^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Uveal Melanoma

Related cancers:
1d
Histone H2A deubiquitinase BAP1 is required for human neuronal progenitor cell formation. (PubMed, Differentiation)
We differentiated human pluripotent stem cells into the neuronal lineage and depleted BAP1 via doxycycline inducible shRNA...Bulk RNA seq analysis showed that neuronal progenitor and neural crest specific transcripts were reduced while surface ectoderm transcripts were higher in BAP1 depleted cells. Thus, our results clearly demonstrate that BAP1 is required for human neuronal progenitor cell formation, since it regulates neuronal and EMT genes.
Journal
|
BAP1 (BRCA1 Associated Protein 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • TWIST1 (Twist Family BHLH Transcription Factor 1) • ITK (IL2 Inducible T Cell Kinase) • NES (Nestin) • SNAI2 (Snail Family Transcriptional Repressor 2)
6d
IGCMU: Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Centre Jean Perrin | Active, not recruiting --> Recruiting | Trial completion date: Oct 2027 --> Apr 2028 | Trial primary completion date: Oct 2026 --> Apr 2028
Enrollment open • Trial completion date • Trial primary completion date
7d
Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial). (PubMed, J Immunother Cancer)
TILs can be manufactured using the CliniMACS Prodigy. Administration of TIL via HAI was safe and feasible in patients with liver-dominant metastatic uveal melanoma. The used regimen appears insufficient to achieve durable clinical efficacy and implies a need for further testing to obtain conclusive results.
P1 data • Journal • Tumor-infiltrating lymphocyte
|
IL2 (Interleukin 2)
|
melphalan
9d
MicroRNA deregulation as a method for assessing the effectiveness of brachytherapy for choroidal melanoma (PubMed, Vestn Oftalmol)
Analysis of microRNA expression levels in the blood plasma of CM patients can be used to assess the effectiveness of brachytherapy and to monitor patients within the framework of lifelong follow-up.
Journal
|
MIR155 (MicroRNA 155) • MIR223 (MicroRNA 223) • MIR27B (MicroRNA 27b)
9d
Choroidal Tumors (PubMed, Klin Monbl Augenheilkd)
Photodynamic therapy is currently considered the preferred treatment in symptomatic cases.Choroidal metastases represent the most prevalent intraocular malignancies, with a primary origin in breast or lung carcinoma. Multimodal imaging is essential for diagnosis and monitoring, and management requires interdisciplinary coordination.A structured multimodal diagnostic approach is crucial for accurate classification, risk assessment, and individualized therapeutic planning in patients with choroidal tumors.
Journal
|
BAP1 (BRCA1 Associated Protein 1)
9d
Trial completion
|
Keytruda (pembrolizumab) • Yervoy (ipilimumab) • dacarbazine • Kimmtrak (tebentafusp-tebn)
10d
IDE196-009: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma (clinicaltrials.gov)
P2, N=160, Active, not recruiting, IDEAYA Biosciences | Recruiting --> Active, not recruiting
Enrollment closed
|
darovasertib (IDE196)
10d
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov)
P2, N=210, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
sunitinib
11d
UC2288 decreases the viability and metastatic activity of human Uveal Melanoma cells via activating the AMPK/eIF2/ATF4 ER stress axis. (PubMed, Eur J Pharmacol)
These findings were replicated in vivo in a UM cell xenograft model. Taken together, UC2288 represents a promising candidate for further development that targets UM tumours with favourable anti-cancer effects.
Journal
|
ATF4 (Activating Transcription Factor 4)
15d
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver (clinicaltrials.gov)
P=N/A, N=10, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
melphalan
16d
The latest in vitro models for novel uveal melanoma drug discovery: how effective are they and what needs to be done? (PubMed, Expert Opin Drug Discov)
Pairing these 3D models with co-culture techniques could dramatically improve the representativeness of UM models. Researchers should consider testing promising therapeutics on a panel of models representing different UM subtypes, with particular attention to high-risk UM, such as those with BAP1 loss.
Preclinical • Review • Journal
|
BAP1 (BRCA1 Associated Protein 1)
17d
A Rare Case of Paraneoplastic Raynaud's Phenomenon and Uveal Melanoma. (PubMed, Acta Dermatovenerol Croat)
She was diagnosed with uveal melanoma three months prior and was also in a 14-year remission from invasive ductal carcinoma. Investigations confirmed positive antinuclear antibodies (ANA) with PCNA (proliferating cell nuclear antigen) and myositis-specific antibodies including anti-Jo, anti-mitochondrial antibody (AMA-M2), and anti-benzylpenicilloyl antibody (BPO).
Journal
|
PCNA (Proliferating cell nuclear antigen)